Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.

Wegiel, Barbara LU ; Bjartell, Anders LU ; Ekberg, Jenny LU ; Gadaleanu, Virgil ; Brunhoff, Cecilia LU and Persson, Jenny L LU (2005) In Oncogene 24(42). p.6385-6393
Abstract
Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was... (More)
Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
androgen receptor, cyclin A1, VEGF, prostate cancer, Rb, androgen
in
Oncogene
volume
24
issue
42
pages
6385 - 6393
publisher
Nature Publishing Group
external identifiers
  • pmid:16007189
  • wos:000232038200006
  • scopus:27144489029
  • pmid:16007189
ISSN
1476-5594
DOI
10.1038/sj.onc.1208795
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology (Malmö) (013031000), Urology (013243400), Division of Urological Cancers (013243420)
id
31ab4ef0-528b-40db-8d2d-363c7be12c76 (old id 142214)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16007189&dopt=Abstract
date added to LUP
2016-04-01 11:51:25
date last changed
2021-10-10 03:40:25
@article{31ab4ef0-528b-40db-8d2d-363c7be12c76,
  abstract     = {Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer.},
  author       = {Wegiel, Barbara and Bjartell, Anders and Ekberg, Jenny and Gadaleanu, Virgil and Brunhoff, Cecilia and Persson, Jenny L},
  issn         = {1476-5594},
  language     = {eng},
  number       = {42},
  pages        = {6385--6393},
  publisher    = {Nature Publishing Group},
  series       = {Oncogene},
  title        = {A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.},
  url          = {http://dx.doi.org/10.1038/sj.onc.1208795},
  doi          = {10.1038/sj.onc.1208795},
  volume       = {24},
  year         = {2005},
}